Lyka Labs Limited has received a favorable order from the National Company Law Appellate Tribunal (NCLAT), New Delhi, Principal Bench, directing Modi Life Care Industries Limited to pay a claim amount of ₹63,00,000. The order, received on June 04, 2026, requires the payment to be made within 30 days from the date of the order. The ruling was issued in relation to Company Appeal (AT) INS.NO. 726 of 2024 filed by Lyka Labs against Modi Life Care Industries under Section 61 of the Insolvency and Bankruptcy Code 2016.

The disclosure was made to the exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The company stated that the receipt of this amount is the only material impact expected from the order, with no significant effect on its broader financial or operational activities.

Details of the Order

The following table outlines the key particulars of the regulatory disclosure and the tribunal's directive:

The filing was signed by Shailendra Agrawal, Company Secretary of Lyka Labs Limited.

Lyka Labs Limited has reported a standalone net loss of ₹322.88 crore for the financial year ended March 31, 2026, a reversal from the net profit of ₹79.18 crore recorded in the previous fiscal year. The consolidated financial results for the year also reflected a net loss of ₹104.36 crore. The decline was primarily driven by the recognition of an exceptional impairment loss amounting to ₹230.14 crore regarding its investment and loans in subsidiary Lyka BDR International Limited. The Board of Directors approved the audited financial results during a meeting held on May 25, 2026.

Financial Performance for FY26

Standalone revenue from operations for the year decreased to ₹120.90 crore from ₹134.69 crore in the prior year. Total income for FY26 stood at ₹124.87 crore, compared to ₹137.45 crore in FY25. Total expenses rose to ₹135.10 crore from ₹126.35 crore year-on-year. The company reported a profit before exceptional items and tax of ₹(10.22) crore, compared to ₹11.10 crore in the previous year. On a consolidated basis, total income from operations was ₹131.94 crore.

Exceptional Impairment Charge

A key factor impacting the financials was the recognition of an impairment loss amounting to ₹230.14 crore. This charge relates to the company's investment and loans in its subsidiary, Lyka BDR International Limited. The impairment was necessitated by continuous operational losses and the severe erosion of the subsidiary's net worth. Consequently, the carrying value of these investments and loans has been reduced to Nil.

Quarterly Results

For the quarter ended March 31, 2026, the company reported a standalone net loss of ₹29.77 crore. Revenue from operations for the quarter was ₹28.54 crore, while total expenses stood at ₹35.43 crore. The exceptional item of ₹230.14 crore was recorded during this quarter, significantly affecting the bottom line. On a consolidated basis, the net loss for the quarter was ₹8.07 crore.

Corporate Actions

The Board has fixed June 4, 2026, as the record date to determine shareholders eligible to receive equity shares pursuant to the Scheme of Amalgamation with Lyka Exports Limited. Shareholders will receive 23 fully paid-up equity shares of ₹10 each for every 100 shares held. The 47th Annual General Meeting is scheduled for August 10, 2026.

Key Financial Metrics

The following table outlines the standalone and consolidated financial performance for the year ended March 31, 2026:

M/s. D. Kothary & Co., Statutory Auditors, have issued an unmodified opinion on the audited financial results.